Introduction
About 65 million persons in the US have hypertension and about 45% (29 million) are on antihypertensive therapy. 1 Blood pressure (BP) response and clinical outcome result to any single drug is characterized by marked interindividual variation, thus limiting identification of the optimum medication for an individual patient. 2 However, the analysis of genetic variation has the potential to improve our understanding of determinants of antihypertensive drug response in order to individualize drug selection. [3] [4] [5] [6] Knowledge about druggene interactions could improve clinical outcomes and possibly reduce treatment costs.
Adducin, a cytoskeletal protein, is a heterodimer or heterotetramer of a-and b-subunits that is critical for the assembly of the actin-spectrin network and has been implicated in cell signal transduction. A potential interaction between diuretics and the a-adducin gene may exist because carriers of the Trp allele of the Gly460Trp polymorphism of this gene are more likely to have renal sodium retention and salt-sensitive hypertension. 7 Also, a-adducin genotypes are associated with BP levels or the prevalence of hypertension in some but not all populations (Caucasian, African-American, Japanese). [8] [9] [10] [11] [12] Blood pressure response to diuretics has been reported to be more pronounced in participants with the Trp allele compared to those homozygous for the Gly allele. 5, 7 To determine whether the a-adducin Gly460Trp polymorphism interacts with type of antihypertensive drug to modify risk of coronary heart disease (CHD) and other cardiovascular disease (CVD) outcomes, the Genetics of Hypertension-Associated Treatment (GenHAT) study examined genotype-treatment interaction in participants from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). 13, 14 Materials and methods
Study design
The design of the GenHAT study has been described in detail elsewhere. 14 The Genetics of Hypertension Associated Treatment study is an ancillary study of ALLHAT, 13 a randomized, double-blind, clinical trial of 42 418 participants. ALLHAT was designed to determine if the incidence of fatal CHD or nonfatal myocardial infarction (MI) in highrisk hypertensive patients is lower with treatment with any of three newer antihypertensive drug classes: a calcium channel blocker (amlodipine ), an angiotensin-converting enzyme (ACE) inhibitor (lisinopril), and an a-adrenergic blocker (doxazosin), each compared to treatment with a diuretic (chlorthalidone).
Randomization in ALLHAT began in February 1994 and concluded in January 1998. Mean follow-up was 4.9 years. In February 2000, the doxazosin arm was discontinued because of futility for the primary end point (part of the a priori stopping guidelines for ALLHAT) and a significantly increased occurrence of the secondary end point, major CVD, (relative risk (RR), 1.25; 95% confidence interval (CI), 1.17-1.33; Po0.001), especially heart failure (RR, 2.04; 95% CI, 1.79-2.32; Po0.001), in the doxazosin arm compared with the chlorthalidone arm. 15 The ALLHAT recruitment, randomization, treatment, and clinical visits The rationale and design of ALLHAT have been reported. 13 Participants were men and women aged X55 years who had hypertension with at least one additional CHD risk factor. Blood pressure eligibility for ALLHAT was based on current antihypertensive medication use and/or the average of two seated BP measurements during two pre-randomization visits. The additional CHD risk factors included previous MI or stroke, presence of type II diabetes, current cigarette smoking, left ventricular hypertrophy by electrocardiogram or echocardiography, or low high-density lipoprotein (HDL) cholesterol concentration. Informed consent was obtained for each patient and the protocol approved by each participating center's Institutional Review Board.
Unless the drug regimen required tapering for safety reasons, individuals continued prior antihypertensive medications until they received randomized study drug, at which point they stopped taking all previous BP medications. Treatment with the study drug was initiated the day after randomization. Participants were randomized to one of four ALLHAT treatment arms, chlorthalidone, lisinopril, amlodipine, or doxazosin, in a ratio of 1.7:1:1:1, respectively.
Randomization was stratified by clinical center. The treatment was given once daily: chlorthalidone (12.5 mg for the first and second titration (sham) and 25 mg for the third); lisinopril (10, 20, or 40 mg); amlodipine (2.5, 5, or 10 mg); or doxazosin (2, 4, or 8 mg). All study medications were identical in appearance to assure masking. The treatment goal was to achieve BP control (systolic BP (SBP)o140 mm Hg and diastolic BP (DBP)o90 mm Hg) on the lowest possible dosage of the first-step drug. If BP control was not achieved, participants were titrated to the maximum study medication dose, and a second-step open-label agent (atenolol, reserpine, or clonidine) and/or a third-step open-label agent (hydralazine) was added.
Information about compliance to study medication was collected at each clinic visit. At 6 months, about 71% were on one drug, about 26% were on two or more drugs, and about 3% were on no drugs. Routine clinic visits were scheduled at 3-month intervals during the first year and 4-month intervals thereafter.
Outcome measures
The primary outcome for GenHAT (and ALLHAT) was CHD (CHD death or non-fatal MI). Secondary outcomes included all-cause mortality, combined CHD (CHD, coronary revascularization, or hospitalized angina), stroke, combined CVD (combined CHD, stroke, treated but not hospitalized angina, heart failure, or peripheral arterial disease), and end-stage renal disease (ESRD). Further details on ALLHAT end point definitions, surveillance, and quality control are provided elsewhere. 13, 16 Change in BP with treatment at 6 months was also evaluated. Six months was selected as the BPs were available for most participants, and monotherapy was likely maximized before other medications were added.
Genotyping methods
All DNA samples were anonymized as set forth in the 'Report of the Special Emphasis Panel on Opportunities and Obstacles to Genetic Research in NHLBI Clinical Studies.' 17 Genotyping of the a-adducin Gly460Trp polymorphism was performed using the TaqMan assay (Applied Biosystems, Foster City, CA, USA). Oligonucleoide sequences for the PCR primers and Taqman probes are available upon request from the authors and have been described previously. 18 Allele detection and genotype calling were performed using an ABI 7900HT and associated Sequence Detection System software (Applied Biosystems). Ongoing quality control analyses were conducted using a 5% blind duplicate replicate; agreement between repeated genotypes was 96%.
Statistical methods
The primary hypothesis was that the effect of the type of antihypertensive medication -chlorthalidone (C) versus the aggregate of lisinopril (L), amlodipine (A), and doxazosin (D) (hereafter, referred to as L þ A þ D) -on CHD risk in high-risk hypertensive persons differs across genotypes of the a-adducin gene. More specifically, the hypothesis was that the RR of CHD for patients randomized to C versus those randomized to L þ A þ D would be lower in Trp allele carriers compared to the analogous relative risk in GlyGly homozygotes.
As the doxazosin arm of the trial was terminated early, there was differential follow-up in this arm compared to the other three. Therefore, we performed two comparisons: (1) C versus L þ A for the full follow-up period that ended in March 2002 and (2) C versus D for the shortened follow-up period that ended in February 2000. As secondary hypotheses, we examined (1) the primary outcome with different comparator groups, for example, chlorthalidone versus lisinopril, amlodipine, or doxazosin (i.e., unaggregated treatments) and (2) secondary outcome genotype-treatment interactions. Six-month BP change was examined using the original aggregated groups, as there was no differential follow-up during this time.
Using the fixed sample size provided by ALLHAT and the available blood samples, the expected genotype frequencies (accounting for the known ethnic distribution within ALLHAT where possible) for the a-adducin gene, the estimated CHD rates for the treatment groups, and a test for a ratio of hazard ratios (HRs) in a 2 Â 2 design (two treatments and two genotypes), there was 80% power with a type 1 family-wise error of 0.05 to detect a ratio of HRs of 0.68 for the primary hypothesis.
14 This is equivalent to a Pvalue of 0.0178/6 ¼ 0.003 for each comparison.
Baseline characteristics were compared among the three genotype groups (GlyGly, GlyTrp, and TrpTrp) using w 2 tests for categorical variables or analysis of variance for continuous variables. Hardy-Weinberg equilibrium was tested using a w 2 goodness-of-fit test. Differences between the groups in the effects of the treatments on BP were investigated using analysis of covariance with the appropriate interaction terms comparing baseline to 6-month (visit window73 months) BP measurements. Incidence of clinical outcomes between a-adducin genotypes and treatment groups were investigated using the Cox proportional hazards model. Hazard ratios (hereafter referred to as relative risks) and 95% CIs were calculated. The RRs for comparison of Trp allele carriers to GlyGly homozygotes with regard to clinical outcomes were also adjusted for selected baseline factors to control for possible confounding. These factors included age, race, sex, history of diabetes, current smoking, history of coronary heart disease, body mass index, and use of prior antihypertensive medications. Homogeneity of the effects of treatment across different genotypes was tested by adding interaction terms to the relevant statistical models. All proportional hazards model analyses presented herein compare Trp allele carriers to GlyGly homozygotes.
Results

Study population and baseline characteristics
The a-adducin genotyped subsample included 36 913 participants: 7911 in the lisinopril group; 7885 in the doxazosin group; 7848 in the amlodipine group; and 13 269 in the chlorthalidone group. These individuals were representative of the total 42 418 ALLHAT participants in terms of their baseline characteristics. 15, 16 Baseline characteristics according to the a-adducin genotypes are presented in Table 1 . GlyGly homozygotes were significantly (Po0.0001) more frequent than the Trp allele carriers in black participants than in non-black participants, but all ethnic group genotypes were in Hardy-Weinberg equilibrium. There were no differences in baseline SBP or DBP levels across the three genotypes. For those who were not taking BP-lowering medications at study entry, there was a DBP difference of 2.2 mm Hg (DBP highest in GlyGly homozygotes, P ¼ 0.015). However, prevalence of MI or stroke, coronary artery bypass surgery, and estrogen replacement therapy was lowest in the GlyGly homozygotes, whereas mean concentrations of HDL cholesterol were highest in the GlyGly homozygotes. The proportions between the three genotypes assigned to each randomized treatment were well balanced.
Effects of a-adducin genotype on 6-month BP changes Six-month BP change according to genotype and treatment assignment is presented in Table 2 . There was an identical SBP response to chlorthalidone in Trp allele carriers (À7.42 mm Hg) and non-carriers (À7.44 mm Hg) with P ¼ 0.962, whereas diastolic blood pressure (DBP) reduction was very slightly smaller in Trp allele carriers (À3.23 and À3.57 mm Hg, respectively) with P ¼ 0.116. The BP advantage of chlorthalidone over the aggregated group (L þ A þ D) was greater in GlyGly homozygotes (À2.75/À0.24 mm Hg) than in Trp allele carriers (À1.56/ þ 0.59 mm Hg; P ¼ 0.076 for SBP; P ¼ 0.005 for DBP). Most of this differential comes from the C versus L comparison, À3.53/À0.94 mm Hg for GlyGly homozygtoes versus À1.38/ þ 0.36 mm Hg for Trp allele carriers; P ¼ 0.033 for systolic blood pressure (SBP); Po0.001 for DBP. These results are quite similar when adjusted for ethnicity.
The effects of the a-adducin genotype on 6-month BP changes by treatment assignment were also investigated among subgroups (i.e., gender, ethnicity, age, and presence of diabetes groups). The BP response in these subgroups was comparable to the overall results; that is, there were no subgroup-genotype-treatment interactions for 6-month changes in SBP or DBP (data not shown). For men, the results for L þ A þ D versus C for GlyGly homozygotes were À2.50/À0.12 mm Hg and for Trp allele carriers were À1.24/ þ 1.03 mm Hg; for women, they were À3.03/À0.38 and À1.97/ þ 0.04 mm Hg, respectively. a-Adducin and BP drugs: effect on BP and CVD Abbreviations: CABG, coronary artery bypass graft; CVD, cardiovascular disease; DBP, diastolic blood pressure; GG, GlyGly; GT, GlyTrp; HDL-C, high-density lipoprotein C; LVH, left ventricular hypertrophy; MI, myocardial infarction; SBP, systolic blood pressure; TT, TrpTrp.
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Associations of a-adducin genotypes with the risk of clinical outcomes The effect of the a-adducin polymorphism was first evaluated for the main outcome and the secondary outcomes. We identified no differential in risk for Trp allele carriers compared to GlyGly homozyotes (see Figure 1) for CHD (HR, 1.05; 95% CI, 0.96-1.14 for C/(A þ L) and HR, 1.07; 95% CI, 0.94-1.21 for C/D) and most of the secondary Figure 1 Hazard ratios (Trp allele carriers group versus GlyGly homozygotes) for Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) primary and secondary outcomes. Difference across treatment groups of mean differences of blood pressure change (mm Hg) between genotypes (GlyTrp+TrpTrp minus GlyGly) plus P-value for interaction (e.g., À1.19 mm Hg SBP ¼ À1.17 for L+A+D, À0.02 for C, P ¼ 0.076).
outcomes. Trp allele carriers had a statistically significant higher risk of combined CHD and combined CVD compared with GlyGly homozygotes (C þ A þ L). These results were mainly driven by the outcomes of angina (and hospitalized angina) and coronary revascularizations, which also had the same pattern of higher risk for Trp allele carriers versus GlyGly homozygotes. However, when these comparisons were adjusted for ethnicity (black versus non-black subjects), the RRs diminished and the results were no longer significant. Also, Trp allele carriers had a lower risk for end-stage renal disease compared with GlyGly homozygotes (RR, 0.72; 95% CI, 0.56-0.92 for C þ A þ L). Adjusted for ethnicity, the RR was 0.83; 95% CI, 0.65-1.07. We estimated the cumulative event rates by genotypedrug combinations, and the results are provided in Table 3 for 6 years of follow-up for the C versus L þ A, C versus L, and C versus A comparisons, and 4 years of follow-up for the C versus D comparison. The event rates for the primary and secondary outcomes were remarkably similar across all genotype-treatment strata with the exception of cancer for C versus D. Kaplan-Meier survival curves for CHD, all-cause mortality, stroke, and combined CVD according to aadducin genotype and treatment are illustrated in Figure 2 , confirming the absence of a significant treatment difference by a-adducin genotypes. For any outcome except cancer, there was no statistical evidence that the effects of treatment varied between the Trp allele carriers and non-carriers (ratios of RRs for TRP allele carriers versus GlyGly homozyotes by antihypertensive agents were all close to 1.0; all values P40.14; Figure 3 ). For the C versus D comparison of cancer incidence, there was a statistically significant interaction between a-adducin genotype and antihypertensive treatment, ratio of RRs of 1.41; 95% CI, 1.05-1.89. When the analysis accounted for current cigarette smoking, the result was a ratio of RRs of 1.27; 95% CI, 0.91-1.77.
We evaluated gene-drug interactions in relation to the main outcome and secondary outcomes in pre-defined subgroups based on ethnicity, gender, age, and presence of diabetes.
The absence of gene-treatment interactions persisted for the ethnicity, age, and presence of diabetes subgroups. However, there was evidence for a difference in the risk of the primary and some secondary outcomes across gendergene-drug subgroups (Figure 4) . Women who were Trp allele carriers and treated with C versus L þ A had a significantly increased risk of CHD (RR, 1.31; 95% CI, 1.02-1.68), whereas those who were GlyGly homozygotes had a nonsignificant decrease in risk (RR, 0.87; 95% CI, 0.75-1.01) for a ratio of RRs of 1.51; 95% CI, 1.13-2.02. Men who were Trp allele carriers had no appreciable difference in risk (RR, 0.91; 95% CI, 0.76-1.10) as did the GlyGly homozygotes (RR, 1.06; 95% CI, 0.95-1.19) for a ratio of RRs of 0.85; 95% CI, 0.69-1.06. The test for gender-gene-treatment interaction yielded P ¼ 0.002. Similar results and gender-gene-treatment interactions were observed for combined CHD (Po0.001), combined CVD (P ¼ 0.009), heart failure (P ¼ 0.001), hospitalized/fatal heart failure (P ¼ 0.006), hospitalized angina (P ¼ 0.04), and coronary revascularizations (P ¼ 0.066). Also, the results were of similar magnitude and direction when examined as C versus L or C versus A or when adjusted for ethnicity, age, presence of diabetes, history of CHD, current smoking, aspirin use, lipid-lowering medication use, and estrogen use (women only). There were no significant gender-gene-drug interactions for C versus D.
Discussion
The a-adducin Gly460Trp genotype was not associated with the primary outcome overall nor for most of the secondary outcomes. However, subgroup analyses indicated a possibly greater risk of treatment with C compared with L þ A for the primary and several related secondary outcomes in women Trp allele carriers compared with GlyGly homozygote women.
A prior study has shown a relationship between the aadducin polymorphism and end-stage renal disease. 19 A case-control study of 260 ESRD patients and 260 controls showed a more rapid progression to ESRD for GlyGly homozygotes compared with Trp allele carriers. The Gen-HAT finding of a possible association for ESRD and aadducin genotype is consistent with this, although the casecontrol study was in a white population and the GenHAT result diminished when adjusted for ethnicity. Further exploration of this result in other studies is needed.
The GenHAT result suggesting an interaction effect of treatment (C versus D) by a-adducin genotype also needs to be explored in other studies. There are studies that suggest that a-blockers may have some role in the development of prostate cancer, 20, 21 but there are no studies relating this polymoprhism, antihypertensive treatment, and cancer. Furthermore, the GenHAT interaction result diminished when adjusted for cigarette smoking.
One study showed that the a-adducin polymorphism is not associated with stroke but is associated with CHD. 18 In GenHAT, we found no associations between these outcomes and the polymorphism. Another investigation involved 22 a population-based case-control study of 715 controls, 206 MIs, and 117 strokes enrolled in a health maintenance organization. Here, in Trp allele carriers, diuretics, in general, and thiazide diuretics, specifically, were associated with a significantly lower risk (about one-half) of combined MI or stroke than other antihypertensive therapies (bblockers, ACE inhibitors, calcium channel blockers, and other vasodilators). The results were similar for MI only and stroke only (not statistically significant). The GenHAT results show no gene-treatment interaction for CHD or stroke. Interestingly, this case-control study showed a similar trend for a gender-genotype-treatment interaction with men faring better on a diuretic than women. In that study, for MI or stroke, the odds ratio (OR) for men/women was 0.19/0.61 (P ¼ 0.07 for sex difference), for MI only, 0.22/ 0.58 for MI or stroke, and for stroke only 0.16/0.58. In GenHAT, for CHD or stroke, the RRs for men/women were 0.96/1.37 (P ¼ 0.02 for sex difference), for CHD only, 0.85/ 1.51 (P ¼ 0.002), and for stroke only 1.06/1.26 (P ¼ 0.49).
a-Adducin and BP drugs: effect on BP and CVD Table 3 Total number of Four-year event rate per 100 persons. Abbrevaitions: CHD, coronary heart disease; CVD, cardiovascular disease; GG, GlyGly; GT, GlyTrp; HF, heart failure; TT, TrpTrp.
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a-Adducin and BP drugs: effect on BP and CVD Why do the case-control and GenHAT studies have different results? One explanation is the different study designs, that is, case-control study versus a randomized, double-blind, clinical trial. The latter assures that there is balance between the treatment groups for both known and unknown factors. The former is subject to bias because it does not assure balance. There may be confounding by indication in case-control studies involving drug treatment -that is, why were patients put on certain types of medication? Within the case-control study, there was a reduced risk (OR, 0.47; 95% CI, 0.26-0.86) for the nonfatal MI outcome for diuretic compared to other drugs overall. No such reduced risk was noted in ALLHAT for the CHD outcome 16 nor for nonfatal MI (RR, 1.07; 95% CI, 0.84-1.37).
Other studies have examined the relationship of the aadducin polymorphism to BP response. In a study by Turner et al., 23 a sample of 291 non-Hispanic black and 294 nonHispanic white subjects between 30 and 60 years of age who had hypertension, the relationship of BP response to diuretic therapy was examined for its association with the a-adducin polymorphism. Previous antihypertensive drug therapy was withdrawn for at least 4 weeks, and subjects were then treated with hydrochlorothiazide (25 mg daily) for 4 weeks to determine BP response. After adjustment for covariates of ethnicity, gender, age, and waist-to-hip ratio, the a-adducin polymorphism made no statistically significant contributions to prediction of BP response.
Cusi et al. 7 undertook a treatment study that was neither a case-control study nor a randomized controlled trial. It was a prospective observational study of 58 persons with essential hypertension who attended a hypertension clinic. They found that there were no differences in baseline BP among those with and without the Trp allele and that, when treated with hydrochlorothiazide, Trp allele carriers had a greater drop in mean arterial BP than GlyGly homozygotes. In GenHAT, there were no differences in baseline BP among those with and without the Trp allele except for DPB in GlyGly versus TrpTrp among those with no prior use of antihypertensive medications of about 2.2 mm Hg, P ¼ 0.015. We also found essentially no difference in SBP or DPB changes among those treated with chlorthalidone a-Adducin and BP drugs: effect on BP and CVD for 6 months in those with and without the Trp allele. No differences were seen when we limited our sample to nonHispanic white subjects and/or persons with no prior use of antihypertensive medications. Factors that may contribute to this difference between studies include different populations, different study designs, different sample sizes, and different medication regimens. A recent study 24 also found no association between the a-adducin polymorphism and diuretic use in lowering BP.
Sciarrone et al. 5 evaluated the BP response to hydrochlorothiazide in 87 never-treated individuals with mild essential hypertension according to ACE gene I/D and a-adducin polymorphisms. Blood pressure was measured after three run-in visits and after the first and second months of treatment by means of a standardized procedure. Patients carrying at least one ACE I allele and one a-adducin Trp allele had the largest decrease in mean arterial BP with treatment (12.771.9 mm Hg), and the effect of the combination of genotypes was additive. The investigators stated that a-adducin and ACE I/D polymorphisms may be useful to predict the interindividual degree of response to hydrochlorothiazide in that the analysis of the combination of the two genotypes increased the accuracy of the prediction of response to the drug.
Glorioso et al., 25 studied the BP response to 2 months of hydrochlorothiazide therapy in 143 persons genotyped for the a-adducin polymorphism. Blood pressure fall after diuretic therapy was more pronounced (Po0.01) in hypertensive persons carrying at least one Trp allele than in GlyGly homozygotes.
The a-adducin gene affects BP by modulating renal tubular sodium absorption of sodium through the activation of Na þ , K þ -ATPase (adenosine triphosphatase). The Trp allele exhibits higher affinity for the Na þ , K þ -ATPase pump, resulting in the loss of ability to alter ion transport. The end result is renal sodium retention in addition to effects of other determinants of tubular sodium reabsorption. 26 Several studies have addressed the question of whether carriers of the Trp allele of the a-adducin gene possibly contribute to the pathogenesis of essential hypertension. 7, 12, [26] [27] [28] [29] [30] [31] [32] The overall evidence from these experimental and clinical studies indicates that Trp allele carriers have an increased risk of hypertension attributable to an innate stimulation of the sodium pump and enhanced renal tubular sodium reabsorption. 7, [33] [34] [35] [36] [37] However, most studies in humans suggest that mutation of the a-adducin gene on its own is insufficient to cause hypertension. 12 Indeed, the pathogenesis of high BP is complex, involves multiple genes, and lifestyle and environmental factors. 38 There is precedent for gene-by-sex interactions for both BP levels and the response to BP-lowering medication. Yamagishi et al. 39 showed that the a-adducin TrpTrp genotype was associated with higher systolic BP among men with a higher sodium intake, whereas there was no such association in women. Wang et al. 40 showed that the 1797T allele of the b-adducin gene is associated with increased risk of hypertension in post-menopausal women, particularly in the presence of the a-adducin Trp allele. Schwartz et al. 41 showed that there was an interaction between sex and the ACE I/D polymorphism for response to a thiazide diuretic. The differences observed between sex and hypertension or sex and the response to thiazide diuretic may be owing to the role of the renin-angiotensin-aldosterone system. Bachman et al. 42 reported that there may be sex difference in the antinatriuretic actions of angiotensin II. Therefore, Trp carriers would be associated with a reduced response to diuretics in women but not in men, as inhibition of plasma renin activity and adrenal aldosterone secretion may represent a counter-regulatory mechanism in response to the chronic volume expansion associated with Trp carriers.
The strength of the present study is that the data were part of a well-known, carefully conducted, randomized, doubleblind clinical trial. The weakness is the absence of a placebo comparison. However, using the method of Davis et al. 43 to assess putative gene-treatment (active versus placebo) interactions and information (data not shown) from another large placebo-controlled hypertension study, the Systolic Hypertension in the Elderly Program, 44, 45 there Figure 4 Gene-treatment interactions (ratio (Trp allele carriers versus GlyGly homozygotes) of hazard ratios (chlorthalidone (C) versus amlodipine (A) þ lisinopril (L))) for men and women. *P-value for gender-gene-treatment interaction.
a-Adducin and BP drugs: effect on BP and CVD appears to be no significant gene-treatment interaction effect for the primary outcome wherein diuretics would be compared with placebo. Using the same method, and the fact that there was no gender-treatment effect in systolic hypertension trial, a treatment (diuretic versus placebo)-gene-gender effect could be inferred. In other words, diuretic would increase CHD risk compared with placebo for women with at least one Trp allele. An additional limitation is that many comparisons were done. Fourteen clinical outcomes were examined, many of which were correlated. Using four subgroup classes (age, ethnicity, sex, presence of diabetes), there were a total of 56 possible subgroup-genotype-treatment interactions. Only five were significant at the Po0.01. However, they were all for cardiovascular outcomes for the sex-genotype-treatment interaction.
In conclusion, GenHAT demonstrates that the a-adducin polymorphism is not an important modifier of antihypertensive treatment effect on CHD risk for men, but suggests that women Trp allele carriers may have an increased CHD risk if treated with chlorthalidone compared with amlodipine or lisinopril. This finding needs to be confirmed in other studies if it is to have implications for hypertension treatment.
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